ANTITUMOR EFFECT OF COMBINATION OF CYCLOPHOSPHAMIDE, ADRIAMYCIN AND PLATINUM (CAP) VERSUS CYCLOPHOSPHAMIDE, ADRIAMYCIN AND 5-FLUOROURACIL (CAF) IN METASTATIC BREAST-CANCER

The aim of the present study was to evaluate the antitumor effect of two drug combinations in disseminated breast cancer. Eighty-one patients divided into two groups entered this nonrandomized study. Group 1 included 32 patients treated with CAP combination: Cyclophosphamide - 200 mg/m2 on days 1, 3 and 5 + adriamycin - 40 mg/m2 on day 1 + cisplatin - 30 mg/m2 on days 1, 3 and 5. Group 2 included 49 patients treated with CAF combination: Cyclophosphamide - 100 mg/m2 on days 1 to 14 + adriamycin - 30 mg/m2 on days 1 and 8 + 5-fluorouracil - 500 mg/m2 on days 1 and 8. All patients had at least 2 courses of chemotherapy. In Group 1 the remission rate was 50% (16 patients) including 3 complete (9%) and 13 partial remissions (41%). In Group 2 the remission rate was 39% (18 patients) with 8 complete (16%) and 10 partial remissions (23%). The analysis of duration of the remissions showed a tendency towards longer duration after treatment with CAP combination (25 versus 15 months for the complete remissions, and 14 versus 11 months for the partial remissions).